Albuferon 900-mcg Every Two Weeks (Albuferon 900 Q2w)
-- Based on an intention-to-treat (ITT) analysis, 58.5% of patients in the
Albuferon 900 Q2w treatment group achieved SVR, vs. 57.9% for
peginterferon alfa-2a administered every week.
-- In heavier patients (75 kg or heavier) who were treatment-adherent,
74.2% of those in the Albuferon 900 Q2w treatment group achieved SVR,
versus 53.3% for peginterferon alfa-2a.
-- Among all treatment-adherent patients in the Albuferon 900 Q2w
treatment group, 72.3% achieved SVR, versus 66.7% for peginterferon
-- Based on the SF-36 Health Survey, patients in the Albuferon 900 Q2w
treatment group reported less impairment of health-related quality of
life, compared with patients in the peginterferon alfa-2a treatment
group, as measured by both physical component and mental component SF-
36 summary measures at all time-points throughout the 48-week treatment
-- Significantly fewer working patients in the Albuferon 900 Q2w treatment
group reported missing 7 days or more of work during the month prior to
their visits at Weeks 12 and 24, vs. the peginterferon alfa-2a group
(p<.05; Week 12: 4.2% for Albuferon 900 Q2w vs. 18.1% for
peginterferon alfa-2a; Week 24: 5.3% for Albuferon 900 Q2w, vs. 20.3%
for peginterferon alfa-2a).
-- The rate of discontinuations due to adverse events was 9.3% in the
Albuferon 900 Q2w treatment group, vs. 6.1% in the peginterferon alfa-
2a group. Adverse events observed were those typically expected with
|SOURCE Human Genome Sciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved